Small Molecules, Big Impact: An Interview with Dr. Cheryl London

Explore the history and impact of small molecules in this fascinating discussion. FidoCure’s Chief Medical Officer, Dr. Gerry Post interviews Dr. Cheryl London about their application in canine cancer treatment.

Dr. Cheryl London is a world-renowned expert in veterinary oncology and targeted cancer therapies at Tufts University. Her pioneering work began in 2000 when she collaborated with SUGEN to develop Palladia, one of the first targeted small molecule drugs approved for veterinary use, treating canine mast cell tumors driven by KIT mutations.

Leave a Reply Cancel reply

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. Access to therapy is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.